Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer
Grubmüller B., Rasul S., Baltzer P., Fajkovic H., D'Andrea D., Berndl F., Maj-Hes A., Grubmüller K. H., Mitterhauser M., Wadsak W., Pfaff S., Shariat Sh., Hacker M., Kramer G., Hartenbach M.
Prostate
Vol.80, Issue1, P. 74-82
Опубликовано: 2020
Тип ресурса: Статья
Аннотация:
Background: To assess which parameters of [68Ga]Ga-PSMA-11 positron emission tomography (PSMA-PET) predict response to systemic therapies in metastatic (m) castration-resistant prostate cancer (CRPC). In addition, to investigate which of these factors are associated with overall survival (OS). Methods: We retrospectively assessed the following PSMA-PET parameters in 43 patients before and after systemic therapies for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, and SUVpeak. prostate-specific antigen (PSA) levels and PSMA-PET/CT(magnetic resonance imaging [MRI]) imaging were both performed within 8 weeks before and 6 weeks after systemic therapy. PSMA-PET and CT (MRI) images were reviewed according to the modified PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Results were compared to PSA response. Univariable survival analyses were performed. Results: Overall, 43 patients undergoi
Ключевые слова:
hybrid imaging; metastatic prostate cancer; PET/CT; PET/MRI; PSMA ligand
abiraterone; antineoplastic agent; cabazitaxel; docetaxel; enzalutamide; gallium prostate specific membrane antigen ga 68; prostate specific antigen; radiopharmaceutical agent; radium 223; unclassified drug; edetic acid; gallium; Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)); oligopeptide; radiopharmaceutical agent; aged; Article; cancer chemotherapy; cancer mortality; cancer survival; castration resistant prostate cancer; clinical article; follow up; human; male; maximum standardized uptake value; mean standardized uptake value; metastasis; multiple cycle treatment; nuclear magnetic resonance imaging; outcome assessment; overall survival; PET response criteria in solid tumor; positron emission tomography-computed tomography; prediction; priority journal; prostate metastasis; response evaluation criteria in solid tumors; retrospective study; systemic therapy; total tumor volume; tumor volume; castration resistant prostate cancer; diagnostic imaging; metastasis; positron emission tomography
Язык текста: Английский
ISSN: 1097-0045
Grubmüller B.
Rasul S.
Baltzer P.
Fajkovic H.
D'Andrea D.
Berndl F.
Maj-Hes A.
Grubmüller K. H.
Mitterhauser M.
Wadsak W.
Pfaff S.
Shariat Sh. Sharokh 1973-
Hacker M.
Kramer G.
Hartenbach M.
Грубмüллер Б.
Расул С.
Балтзер П.
Файковиc Х.
Д'Андреа Д.
Берндл Ф.
Май-Хес А.
Грубмüллер К. Х.
Миттерхаусер М.
Wадсак W.
Пфафф С.
Шариат Ш. Шарох 1973-
Хаcкер М.
Крамер Г.
Хартенбач М.
Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer
Текст визуальный непосредственный
Prostate
John Wiley & Sons
Vol.80, Issue1 P. 74-82
2020
Статья
hybrid imaging metastatic prostate cancer PET/CT PET/MRI PSMA ligand
abiraterone antineoplastic agent cabazitaxel docetaxel enzalutamide gallium prostate specific membrane antigen ga 68 prostate specific antigen radiopharmaceutical agent radium 223 unclassified drug edetic acid gallium Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) oligopeptide radiopharmaceutical agent aged Article cancer chemotherapy cancer mortality cancer survival castration resistant prostate cancer clinical article follow up human male maximum standardized uptake value mean standardized uptake value metastasis multiple cycle treatment nuclear magnetic resonance imaging outcome assessment overall survival PET response criteria in solid tumor positron emission tomography-computed tomography prediction priority journal prostate metastasis response evaluation criteria in solid tumors retrospective study systemic therapy total tumor volume tumor volume castration resistant prostate cancer diagnostic imaging metastasis positron emission tomography
Background: To assess which parameters of [68Ga]Ga-PSMA-11 positron emission tomography (PSMA-PET) predict response to systemic therapies in metastatic (m) castration-resistant prostate cancer (CRPC). In addition, to investigate which of these factors are associated with overall survival (OS). Methods: We retrospectively assessed the following PSMA-PET parameters in 43 patients before and after systemic therapies for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, and SUVpeak. prostate-specific antigen (PSA) levels and PSMA-PET/CT(magnetic resonance imaging [MRI]) imaging were both performed within 8 weeks before and 6 weeks after systemic therapy. PSMA-PET and CT (MRI) images were reviewed according to the modified PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Results were compared to PSA response. Univariable survival analyses were performed. Results: Overall, 43 patients undergoi